Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or VSports app下载. mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

Clinical Trial
. 2015 Mar;168(6):796-805.
doi: 10.1111/bjh.13214. Epub 2014 Nov 17.

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

Robert K Stuart  1 , Larry D Cripe, Michael B Maris, Maureen A Cooper, Richard M Stone, Shaker R Dakhil, Francesco Turturro, Wendy Stock, James Mason, Paul J Shami, Stephen A Strickland, Luciano J Costa, Gautam Borthakur, Glenn C Michelson, Judith A Fox, Richard D Leavitt, Farhad Ravandi
Affiliations
Clinical Trial

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

Robert K Stuart et al. Br J Haematol. 2015 Mar.

Abstract

This phase 2 study (N = 116) evaluated single-agent vosaroxin, a first-in-class anticancer quinolone derivative, in patients ≥60 years of age with previously untreated unfavourable prognosis acute myeloid leukaemia. Dose regimen optimization was explored in sequential cohorts (A: 72 mg/m(2) d 1, 8, 15; B: 72 mg/m(2) d 1, 8; C: 72 mg/m(2) or 90 mg/m(2) d 1, 4). The primary endpoint was combined complete remission rate (complete remission [CR] plus CR with incomplete platelet recovery [CRp]). Common (>20%) grade ≥3 adverse events were thrombocytopenia, febrile neutropenia, anaemia, neutropenia, sepsis, pneumonia, stomatitis and hypokalaemia. Overall CR and CR/CRp rates were 29% and 32%; median overall survival (OS) was 7·0 months; 1-year OS was 34%. Schedule C (72 mg/m(2) ) had the most favourable safety and efficacy profile, with faster haematological recovery (median 27 d) and lowest incidence of aggregate sepsis (24%) and 30-d (7%) and 60-d (17%) all-cause mortality; at this dose and schedule, CR and CR/CRp rates were 31% and 35%, median OS was 7·7 months and 1-year OS was 38%. Overall, vosaroxin resulted in low early mortality and an encouraging response rate; vosaroxin 72 mg/m(2) d 1, 4 is recommended for further study in this population. Registered at www. clinicaltrials. gov: #NCT00607997 VSports手机版. .

Keywords: acute myeloid leukaemia; elderly; newly diagnosed; topoisomerase-II inhibitor; vosaroxin. V体育安卓版.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival outcomes in newly diagnosed acute myeloid leukaemia treated with vosaroxin. (A) Overall survival in the pooled population (N = 113). (B) Leukaemia-free survival in patients with CR/CRp (n = 36). Sch, schedule; CR, complete remission; CRp, complete remission with incomplete platelet recovery; 95% CI, 95% confidence interval.
See this image and copyright information in PMC

References

    1. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE. Petersdorf SH. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485. - PMC - PubMed
    1. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM. Marcucci G. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proceedings of the National Academy of Sciences USA. 2010;107:7473–7478. - VSports app下载 - PMC - PubMed
    1. Burnett A, Wetzler M. Lowenberg B. Therapeutic advances in acute myeloid leukemia. Journal of Clinical Oncology. 2011;29:487–494. - PubMed
    1. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology. 2003;21:4642–4649. - PubMed
    1. Evanchik MJ, Allen D, Yoburn JC, Silverman JA. Hoch U. Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiaz olyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent. Drug Metabolism and Disposition. 2009;37:594–601. - PubMed

Publication types

MeSH terms

Associated data